OR WAIT null SECS
© 2021 MJH Life Sciences and Formulary Watch. All rights reserved.
© 2021 MJH Life Sciences™ and Formulary Watch. All rights reserved.
FDA revisits who can get Biogen's controversial Alzheimer's drug
August 02, 2021
The sickle cell disease therapy will now be on the Preferred Drug List.
July 29, 2021
Drugs that provide only incremental benefit may not be included on clinical pathways.
July 28, 2021
The findings were similar in people with or without diabetes.
July 27, 2021
Competition among branded products did not substantially curb annual spending increases.
July 26, 2021
A substantial discount would be needed to meet cost-effectiveness thresholds.
July 23, 2021
When Medicare D plans do provide coverage for first generics, they are often placed on non-generic tiers.
The June 30 approval meets an unmet need in this cancer.
July 22, 2021
The FDA had approved Kadmon's therapy for graft-versus-host disease July 16.
July 20, 2021
Wynzora is a cream-based, fixed dose combination of calcipotriene and betamethasone for topical treatment of psoriasis.